We focus on developing novel, transformative cancer therapeutics.
Our vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies and by partnering with leading medical centers on the development of our therapeutics.
On January 2021, Biond Biologics and Sanofi signed collaboration agreement for the development and commercialization of BND-22. BND-22 is an antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. Under the terms of the Collaboration Biond received USD 125M upfront payment, potential milestones of up to USD 1B and double-digit royalties. Biond is leading the first-in-human, phase 1a study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics. Sanofi will assume clinical development and commercialization responsibilities thereafter.